(Q37324603)

19 August 2017

1 reference

title

Novel approaches to discovery of antibacterial agents (English)

1 reference

19 August 2017

Patricia L Taylor

1

1 reference

19 August 2017

Gerard D Wright

series ordinal

2

1 reference

19 August 2017

publication date

13 November 2008

1 reference

Animal Health Research Reviews

19 August 2017

published in

1 reference

19 August 2017

volume

9

1 reference

19 August 2017

issue

2

1 reference

19 August 2017

page(s)

237-246

1 reference

Novel pathways for biosynthesis of nucleotide-activated glycero-manno-heptose precursors of bacterial glycoproteins and cell surface polysaccharides

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

Discovery of FabH/FabF inhibitors from natural products

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Trimethoprim and enterococci in urinary tract infections: new perspectives on an old issue

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Natural products to drugs: daptomycin and related lipopeptide antibiotics

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Structure and function of sedoheptulose-7-phosphate isomerase, a critical enzyme for lipopolysaccharide biosynthesis and a target for antibiotic adjuvants

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Lipopolysaccharide endotoxins

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Increased amoxicillin-clavulanic acid resistance in Escherichia coli blood isolates, Spain.

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Functional analysis of the glycero-manno-heptose 7-phosphate kinase domain from the bifunctional HldE protein, which is involved in ADP-L-glycero-D-manno-heptose biosynthesis

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Antivirulence as a new antibacterial approach for chemotherapy

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Coelichelin, a new peptide siderophore encoded by the Streptomyces coelicolor genome: structure prediction from the sequence of its non-ribosomal peptide synthetase

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

The biology and future prospects of antivirulence therapies

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

eSGA: E. coli synthetic genetic array analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Tigecycline: a new glycylcycline antimicrobial.

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Developing a new resource for drug discovery: marine actinomycete bacteria

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Physicochemical properties of antibacterial compounds: implications for drug discovery

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

The therapeutic potential of host-defense antimicrobial peptides

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

A genome-wide strategy for the identification of essential genes in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Bacterial efflux systems and efflux pumps inhibitors

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Essential Bacillus subtilis genes

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

New targets and screening approaches in antimicrobial drug discovery

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Multidrug-resistance efflux pumps - not just for resistance

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Inhibitors of efflux pumps in Gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Renaissance in antibacterial discovery from actinomycetes

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Comparative analysis of essential genes and nonessential genes in Escherichia coli K12.

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

An in vitro screen of bacterial lipopolysaccharide biosynthetic enzymes identifies an inhibitor of ADP-heptose biosynthesis.

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

A complete lipopolysaccharide inner core oligosaccharide is required for resistance of Burkholderia cenocepacia to antimicrobial peptides and bacterial survival in vivo.

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Marine actinomycetes as a source of novel secondary metabolites.

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Conclusions: the future of antimicrobial therapy - Augmentin and beyond

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Meticillin-resistant Staphylococcus aureus in animals: a review

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Isolation and identification of three new 5-alkenyl-3,3(2H)-furanones from two streptomyces species using a genomic screening approach.

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Cell-division inhibitors: new insights for future antibiotics

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Drugs for bad bugs: confronting the challenges of antibacterial discovery

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Discovery of a new peptide natural product by Streptomyces coelicolor genome mining

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Genomic analyses lead to novel secondary metabolites. Part 3. ECO-0501, a novel antibacterial of a new class.

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Tigecycline: the answer to beta-lactam and fluoroquinolone resistance?

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Bacterial efflux pump inhibitors from natural sources.

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Siderophore-based iron acquisition and pathogen control

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Platensimycin is a selective FabF inhibitor with potent antibiotic properties

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144. I. Taxonomy, fermentation, isolation and structural elucidation

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

High throughput screening identifies novel inhibitors of Escherichia coli dihydrofolate reductase that are competitive with dihydrofolate

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

A genomics-guided approach for discovering and expressing cryptic metabolic pathways.

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Dysregulation of bacterial proteolytic machinery by a new class of antibiotics

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

The applications of systematic in-frame, single-gene knockout mutant collection of Escherichia coli K-12.

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli

1 reference

https://api.crossref.org/works/10.1017%2FS1466252308001527

7 January 2021

10.1017/S1466252308001527

Identifiers

DOI

1 reference

19 August 2017

1 reference